WASHINGTON — The Association for Accessible Medicines (AAM) has responded to the Colorado Prescription Drug Affordability Board’s (PDAB) decision to propose a price cap on the brand biologic Enbrel, setting an upper payment limit of $600 — the first such action by a state PDAB in the nation.
“A competitive market is a better solution to lower costs than the government deciding what it’s going to pay,” said AAM president and CEO John Murphy III. “Generic and biosimilar medicines always save patients money and are the only facet of the health care system where prices continue to go down.”
Murphy added that no biosimilar version of Enbrel is currently available in the U.S., despite the existence of biosimilars to the drug in other countries. He called for reforms that uphold the principles of the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA), both of which were designed to promote market-driven competition and patient access.
AAM emphasized that generic and biosimilar medicines continue to generate substantial savings for patients and health plans, far surpassing what can be achieved through government-imposed price caps. The organization’s newly released 2025 U.S. Generic & Biosimilar Medicines Savings Report details these savings, highlighting the crucial role of competition in reducing health care costs.
2025 U.S. Generic & Biosimilar Medicines Savings Report:
https://accessiblemeds.org/resources/reports/2025-savings-report
More information is available at accessiblemeds.org.
